The following primary antibodies were used for immunostaining: Rat anti-BrdU (1:1000, Abcam, #ab6326), Goat anti-GFAP (1:1000, Abcam, #ab53544), Mouse anti-SOX2 (1:1000 ... in the central area of the ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

A mouse with no biological mother has survived to adulthood in China – a major scientific achievement that's been years in the making. The feat was pulled off by a team of researchers in China, led by ...

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...

Wired over wireless peripherals. Mechanical keyboard or nothing. Hall effect switches for controllers. And when it comes to picking the right mouse, high DPI figures are a must. If you've ever run ...